Search Results - fusion+protein

7 Results Sort By:
GENETICALLY ENCODED LYSOSOME TARGETING CHIMERAS FOR CELL-MEDIATED DELIVERY
GENETICALLY ENCODED LYSOSOME TARGETING CHIMERAS FOR CELL-MEDIATED DELIVERY Researchers at Stanford have developed fully genetically-encodable lysosome-targeting chimeras which allow for the targeted delivery of various proteins into receiver cells. Lysosome-targeted degradation is an emerging therapeutic modality that facilitates the degradation...
Published: 11/6/2024   |   Inventor(s): Jonathan Yang, Carolyn Bertozzi, Alice Ting
Keywords(s): Fusion Protein, Lysosome
Category(s): Technology Classifications > Biology
METHODS AND COMPOSITION FOR TARGETED RECEPTOR-MEDIATED PROGRAMMABLE MACROMOLECULE DELIVERY
­METHODS AND COMPOSITION FOR TARGETED RECEPTOR-MEDIATED PROGRAMMABLE MACROMOLECULE DELIVERY Researchers at Stanford have developed a novel method for programmable macromolecule delivery via engineered cells, using trogocytosis. Genome editing technologies have revolutionized the field of personalized medicine. Despite its initial promise, many...
Published: 4/22/2024   |   Inventor(s): Lei Qi, Xinyi Chen, Wendy Fantl
Keywords(s): Fusion Protein, Protein Engineering, Trogocytosis
Category(s): Technology Classifications > Biology
­METHODS AND COMPOSITIONS IN PROGRAMMABLE RECEPTOR FOR ANTIGEN DETECTION AND CUSTOMIZED CELL RESPONSES
­METHODS AND COMPOSITIONS IN PROGRAMMABLE RECEPTOR FOR ANTIGEN DETECTION AND CUSTOMIZED CELL RESPONSES Researchers at Stanford have developed new methods to create programmable synthetic receptors (PAGER). The advent of programmable synthetic receptors represents a new era in cellular therapies and in biomedical science. There are currently tens...
Published: 12/5/2023   |   Inventor(s): Nicholas Kalogriopoulos, Alice Ting, Matthew Ravalin, Reika Tei
Keywords(s): Antibody, Fusion Protein, Receptor
Category(s): Technology Classifications > Biology
Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV
Abstract: Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells.  Different forms of sCD4 and their fusion proteins have been extensively studied in animal models and clinical trials as promising HIV-1 inhibitors. However, they have not been successful in clinical trials due to their transient efficacy.  sCD4 is also known to interact...
Published: 5/22/2024   |   Inventor(s): Dimiter Dimitrov, Weizhao Chen
Keywords(s): CD4, Dimitrov, fusion protein, HIV-1, Single Domain Antibodies (sdAb)
Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing
Fusion Proteins as HIV-1 Entry Inhibitors
Abstract: Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells.  Different forms of sCD4 and their fusion proteins have been extensively studied as promising HIV-1 inhibitors – including in animal models and clinical trials.  However, they have not been successful in human studies due to their transient efficacy.  sCD4 is also known...
Published: 5/22/2024   |   Inventor(s): Dimiter Dimitrov, Weizhao Chen, Tianlei Ying
Keywords(s): antibody dependent cellular cytotoxicity (ADCC), Class II major histocompatibility complex (MHCII), Dimitrov, fusion protein, HIV-1, sCD4
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease
Novel Fusion Proteins for HIV Vaccine
Abstract: Development of successful HIV vaccine immunogens continues to be a major challenge.  Although gp120 was identified as having significant potential as a vaccine immunogen, attempts to elicit broadly neutralizing antibodies using recombinant gp120 failed.  The highly flexible gp120 may present numerous conformations to the humoral immune system...
Published: 12/6/2024   |   Inventor(s): Dimiter Dimitrov, Weizhao Chen
Keywords(s): ANTIBODY, CD4, Dimitrov, fusion protein, gp120, HIV Vaccine
Category(s): TherapeuticArea > Immunology, Application > Research Materials, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing
CORONAVIRUS NEUTRALIZING COMPOSITIONS AND ASSOCIATED METHODS
CORONAVIRUS NEUTRALIZING COMPOSITIONS AND ASSOCIATED METHODS Researchers at CZ Biohub SF and Stanford have developed unique fusion proteins that have broad therapeutic benefits for the treatment of infection by existing and future coronaviruses. Coronaviruses cause human illness ranging from the common cold to more severe diseases. They are large,...
Published: 12/5/2024   |   Inventor(s): Payton Weidenbacher, Peter Kim, Eric Waltari
Keywords(s): Antibody, Broad-Spectrum, Coronavirus, Fusion Protein, Highly-Conserved, Inhibitor, Neutralizing, Receptor, Variant
Category(s): Technology Classifications > Biology